retatrutide phase 2 trial results weight loss obesity triple agonist This week's most cited articles: 1. Original Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial https://t.co/jNL1GNnHPT #Endocrinology What caught my attention wasn't
Description
Activities that were abandoned years ago, playing basketball, hiking, wrestling with the kids, become possible again
Between 2004 and 2009, a total of 2,625 cases of pancreatitis were reported
Members under 21 may still qualify via EPSDT, and non-weight-loss indications (like Zepbound for sleep apnea) may still get prior authorization
This new drug combines semaglutide with amylin and calcitonin receptor agonists
